A Phase I/II Multi-Center, Open Label Study of TKI258 [dovitinib] Administered Orally on an Intermittent Schedule in Adult Patients With Advanced or Metastatic Renal Cell Cancer (RCC).
Phase of Trial: Phase I/II
Latest Information Update: 21 Apr 2015
At a glance
- Drugs Dovitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 12 Nov 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004045).
- 26 May 2012 Planned number of patients changed from 91 to 110 as reported by European Clinical Trials Database record.